Multiple Myeloma

Statistical significance was reached across all end points of the phase 3 GENESIS trial investigating granulocyte colony stimulating factor plus either motixafortide or placebo in patients with multiple myeloma receiving autologous bone marrow transplantation.

Adding daratumumab led to at least a very good partial responses in all 41 patients receiving weekly carfilzomib, lenalidomide, and dexamethasone, and complete responses in all but 2 patients.

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.

Data on the use of ixazomib plus lenalidomide/dexamethasone were similar to results from the pivotal TOURMALINE-MM1 trial, suggesting patients with multiple myeloma in routine practice could achieve similar outcomes to patients treated on clinical trials.

Radowan A. Elnair, MD, and Sarah A. Holstein, MD, PhD, review literature regarding progress in the management of the transplant-ineligible multiple myeloma in an article published in the journal ONCOLOGY®.

A higher mutational load detected by whole-genome sequencing in patients with multiple myeloma precursor conditions was likely predictive of subsequent disease progression.

The FDA approved the addition of isatuximab to the combination of carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

The approval of idecabtagene vicleucel was supported by results from the phase 2 KarMMa trial, which evaluated the safety and efficacy of idecabtagene vicleucel (ide-cel) in patients who had received at least 3 prior regimens and were refractory to their last regimen per IMWG criteria.

Mehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.

Data from the POLLUX and CASTOR trials both found higher sustained MRD-negativity rates for daratumumab combination regimens compared with the standard-of-care treatments.

“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.

Based on phase 2 data, the FDA granted accelerated approval to melphalan flufenamide in combination with dexamethasone for the treatment of multiple myeloma following 4 or more prior lines of therapy.

Results of a phase 2 trial testing the efficacy of idecabtagene vicleucel in patients with heavily pretreated myeloma are reported.

Data regarding patients with previous Hodgkin lymphoma and primary myelofibrosis diagnoses found associations with subsequent diagnosis of multiple myeloma.

Research in the Journal of Clinical Oncology found an association between the combination of daratumumab, lenalidomide, and dexamethasone with improved patient-reported outcomes versus lenalidomide and dexamethasone alone.

The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.

Data published in The Lancet found a favorable tolerability profile for the subcutaneous formulation of bortezomib when compared with previous trials of the combination panobinostat plus dexamethasone and intravenous bortezomib in myeloma.

The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.

Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.